Projects per year
Fingerprint
- 1 Similar Profiles
Network
Projects
- 1 Finished
-
INSTITUTE FOR CANCER RESEARCH AND CARE
Hinck, A. P., Sarantopoulos, J., Curiel, T. J., Lafer, E. M., Weintraub, S. E., Karnad, A. B., Lechleiter, J. D., Thompson, I. M., Leach, R. J., Christy, B. A., Allred, C., Johnson, K., Padmanabhan, S., I-Tien, Y., Naylor, S., Gazitt, Y., Pollock, B. H., Mundy, G., Bonewald, L., Davis, S., Lee, E., Oishi, N., Hasty, E., Vijg, J. N. M. N., Herman, B. A., Johnson, K., Moyer, M., Windle, J., McGill, J., O'Connell, P., Clark, G., Kuhn, J., Wolf, R., Allred, D. C., Weiss, G., Boldt, D., Coltman, C. & Huang, H.
9/1/91 → 7/31/19
Project: Research project
Research output
-
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Hamadani, M., Collins, G. P., Caimi, P. F., Samaniego, F., Spira, A., Davies, A., Radford, J., Menne, T., Karnad, A., Zain, J. M., Fields, P., Havenith, K., Cruz, H. G., He, S., Boni, J., Feingold, J., Wuerthner, J. & Horwitz, S., Jun 2021, In: The Lancet Haematology. 8, 6, p. e433-e445Research output: Contribution to journal › Article › peer-review
-
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R. L., González Mendoza, R., Roy, A., Zhang, Y. & 187 others, , Nov 23 2019, In: The Lancet. 394, 10212, p. 1915-1928 14 p.Research output: Contribution to journal › Article › peer-review
403 Scopus citations -
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L., Masters, G., Oettel, K., Guaglianone, P., Reynolds, C., Karnad, A., Arnold, S. M., Varella-Garcia, M., Moon, J., Mack, P. C., Blanke, C. D., Hirsch, F. R., Kelly, K. & Gandara, D. R., Jan 2018, In: The Lancet Oncology. 19, 1, p. 101-114 14 p.Research output: Contribution to journal › Article › peer-review
40 Scopus citations -
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kelly, K. R., Friedberg, J. W., Park, S. I., McDonagh, K., Hayslip, J., Persky, D., Ruan, J., Puvvada, S., Rosen, P., Iyer, S. P., Stefanovic, A., Bernstein, S. H., Weitman, S., Karnad, A., Monohan, G., VanderWalde, A., Mena, R., Schmelz, M., Spier, C., Groshen, S. & 5 others, , Dec 15 2018, In: Clinical Cancer Research. 24, 24, p. 6150-6159 10 p.Research output: Contribution to journal › Article › peer-review
14 Scopus citations -
The biology and role of CD44 in cancer progression: Therapeutic implications
Chen, C., Zhao, S., Karnad, A. & Freeman, J. W., May 10 2018, In: Journal of Hematology and Oncology. 11, 1, 64.Research output: Contribution to journal › Review article › peer-review
254 Scopus citations